TMS for Alzheimer's Disease and Memory Decline

TMS is not an FDA-authorized treatment for Alzheimer's disease or age-related memory decline in the United States. The one device that sought authorization, the neuroAD system, was reviewed by an FDA advisory panel in 2019, which unanimously judged that its probable benefits did not outweigh its probable risks; no FDA authorization for it was found as of October 2026. TMS for memory is therefore off-label and research-stage.

That is not the same as "it does nothing." Meta-analyses of research trials report measurable gains on cognitive tests, and newer approaches targeting memory networks are being tested seriously. The gap is between promising short-term test scores and proof that TMS changes the course of the illness or daily life.

The neuroAD story: how a memory device fell short at FDA

The neuroAD Therapy System paired TMS with computerized cognitive training. Its U.S. pivotal trial randomized 129 people aged 60 to 90 with mild to moderate Alzheimer's disease to six weeks of daily active or sham treatment, on top of standard care. The published report emphasized a subgroup: participants with milder baseline impairment (an ADAS-Cog score of 30 or less, about 85% of the sample) showed a statistically significant benefit, and 31.7% of active versus 15.4% of sham participants improved by at least 4 ADAS-Cog points.

FDA's Neurological Devices Panel read the same data differently. The panel agreed the pivotal study "did not demonstrate a clinically meaningful benefit" and was unanimous that the probable benefits did not outweigh the probable risks. That gap, between a statistically significant subgroup and a clinically meaningful result, is the core issue across this whole field.

What the broader research shows

Most trials have stimulated the left dorsolateral prefrontal cortex, the same region used for depression; in the 2026 meta-analysis, four of the five trials did. The Koch trial instead targeted the precuneus, a key node of the brain's default mode network, which is altered in Alzheimer's disease, and used a maintenance design: two weeks of daily sessions, then weekly sessions for 22 weeks. Its primary outcome, the Clinical Dementia Rating Sum of Boxes, captures daily function as well as memory, which is why it is often treated as more meaningful than a test score alone. It is the kind of result that justifies larger trials, not routine use. The full trial report is open to read.

Why promising scores have not become standard care

• Protocols vary widely in target, frequency, number of sessions and whether cognitive training is added, so no single regimen has been replicated enough to standardize.
• Follow-up is short. Alzheimer's is a progressive illness, and the question families care about is whether decline slows over a year or more.
• Small effects on the MMSE or ADAS-Cog do not always translate into independence, safety or quality of life.
• Expectation effects matter: daily clinic visits, attention and structured activity can themselves lift test performance.

How to read a headline about TMS and memory

News coverage of this research tends to compress several questions into one. Before drawing conclusions from a new study, it helps to check four things.

• Was there a sham group, and were patients and raters blinded? Without both, improvement cannot be attributed to the stimulation.
• Who was studied? Results in mild cognitive impairment do not automatically apply to moderate Alzheimer's disease, or the reverse.
• What was measured? A better score on a memory test is not the same as staying independent longer.
• How long did the benefit last after treatment stopped, and was maintenance stimulation needed?

Safety in an aging brain

Across the cognitive-disorder literature, TMS was generally well tolerated. In the 2024 review of 143 studies, only two studies reported seizures (four events); three were judged unrelated to TMS and the fourth resolved with coil repositioning. A separate systematic review cited by the 2021 IFCN safety guideline found no reliable evidence of cognitive side effects across 31 randomized trials that included Alzheimer's patients.

Dementia still changes the risk calculation. New York's Medicare policy lists dementia among the neurological conditions that call for caution with TMS, alongside epilepsy, cerebrovascular disease and head trauma. Older adults are also more likely to have pacemakers or other implants that need checking; these and other device questions are covered in TMS safety and seizure risk.

When memory complaints are really depression

This is where TMS most often belongs in an older adult's care. Depression in later life frequently shows up as poor concentration, slowed thinking and forgetfulness, and it can look like early dementia. Unlike Alzheimer's, it is a cleared indication: a 2025 meta-analysis of 10 randomized trials in late-life depression found benefit over control on depression scores, response and remission. In the NeuroStar development program, auditory threshold and cognitive function did not change with treatment.

The sequence matters. A memory complaint deserves a proper evaluation first: cognitive testing, a review of medications, sleep, hearing and mood, and medical causes such as thyroid disease or B12 deficiency, described in ruling out medical causes before TMS. If depression is driving the symptoms and has not responded to medication, TMS for depression is a legitimate option. The patient-facing guide to TMS for older adults covers the practical side.

Coverage reflects the evidence

Medicare in New York covers TMS only for adults with a confirmed diagnosis of major depressive disorder. Optum's behavioral policy lists dementia as an unproven indication, and Cigna's policy treats the newer billing codes for precuneus-targeted TMS as not medically necessary. Anyone offered TMS for memory should expect to pay privately, and should weigh that against the strength of the evidence. Details by payer are in the Medicare TMS coverage guide for New York.

A longevity view without overpromising

Interest in brain health in midlife and beyond is well placed, and memory is a reasonable thing to protect. But the measures most consistently recommended for long-term brain health are unglamorous: treating depression, hearing loss, high blood pressure, diabetes and sleep disorders; regular physical activity; and social and cognitive engagement. The site's longevity psychiatry and exercise and brain health pages go into that work.

TMS for memory may earn a place in that toolkit once larger, longer trials confirm a functional benefit. Today, the responsible route for someone who wants to try it is a registered clinical trial, which offers a defined protocol, monitoring and a contribution to the answer.

Questions to bring to a memory consultation

1. Has a full cognitive and medical workup been done, including screening for depression?
2. If TMS is proposed, is it for depression (a cleared use) or for memory (research-stage)?
3. Which published sham-controlled trial does the protocol follow, and what was its primary outcome?
4. How will benefit be measured, and when would treatment stop if there is none?
5. Is there a clinical trial nearby that would be a better fit?

For how TMS works and what it is cleared for, see the TMS guide and the TMS overview. The mechanism is explained in how TMS works.

Frequently asked questions

Is TMS approved for dementia or Alzheimer's?

No. No TMS device holds FDA authorization for Alzheimer's disease or dementia. An FDA advisory panel reviewed the neuroAD system in 2019 and concluded its benefits did not outweigh its risks.

Can TMS slow memory decline?

A 2022 sham-controlled trial of precuneus stimulation found less decline on a dementia rating scale over 24 weeks, and meta-analyses report short-term gains on cognitive tests. Whether TMS slows the disease long term is not established.

Does TMS for depression harm memory in older adults?

Reviews of randomized trials have not found reliable evidence of cognitive side effects from standard prefrontal TMS. Unlike ECT, it does not require anesthesia.

Is TMS for mild cognitive impairment worth trying?

It remains research-stage. The best way to try it is through a registered clinical trial, after a full workup for treatable causes such as depression, sleep problems, hearing loss or medication effects.

Will Medicare pay for TMS for memory problems?

No. Medicare in New York covers TMS only for adults with major depressive disorder who meet its criteria.

Sources

1. Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment. Journal of Clinical Psychiatry, 2008. europepmc.org
2. Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines. Clinical Neurophysiology, 2021. europepmc.org
3. Repetitive transcranial magnetic stimulation for late-life depression: A systematic review and meta-analysis of randomized controlled trials. Journal of International Medical Research, 2025. europepmc.org
4. Brief Summary of the Neurological Devices Panel Meeting – March 21, 2019: neuroAD Therapy System. U.S. FDA, 2019. fda.gov
5. Efficacy and safety of transcranial magnetic stimulation on cognition in mild cognitive impairment, Alzheimer's disease, Alzheimer's disease-related dementias, and other cognitive disorders: a systematic review and meta-analysis. International Psychogeriatrics, 2024. europepmc.org
6. LCD L33398 Transcranial Magnetic Stimulation (version 40). Wellpoint Federal (formerly National Government Services) via CMS Medicare Coverage Database / CMS Coverage API, 2026. cms.gov
7. Transcranial Magnetic Stimulation (Coverage Policy). Evernorth Health Services (Cigna), 2026. a.static.cigna.com
8. Behavioral Clinical Policy: Transcranial Magnetic Stimulation. Optum Behavioral Health Solutions, 2026. providerexpress.com
9. Effects of a combined transcranial magnetic stimulation (TMS) and cognitive training intervention in patients with Alzheimer's disease. Alzheimer's & Dementia, 2020. europepmc.org
10. Efficacy and Durability of Repetitive Transcranial Magnetic Stimulation on Cognitive Function in Patients With Mild-to-Moderate Alzheimer's Disease: A Systematic Review and Meta-Analysis. Psychogeriatrics, 2026. europepmc.org
11. Precuneus magnetic stimulation for Alzheimer's disease: a randomized, sham-controlled trial. Brain, 2022. europepmc.org
12. Brain Stimulation Therapies. National Institute of Mental Health (NIMH), 2024. nimh.nih.gov

Educational information, not medical advice. Whether TMS or any treatment fits you is a decision to make with a psychiatrist who knows your history.